Bioperfectus Obtained CE Mark for the SARS-CoV-2 Antigen Rapid Self-test

Company news
2021-12-28

Bioperfectus is pleased to announce that we have obtained CE Mark for our Novel Corona Virus (SARS-CoV-2) Ag Rapid Test Kit (Self-test). This test is a lateral flow test intended for non-prescription home use with self-collected nasal swab specimens. It is used to detect symptomatic individuals who are suspected of COVID-19 or asymptomatic individuals who have had contact with confirmed COVID-19 patients but do not show any symptoms.

 

 

Our Novel Corona Virus (SARS-CoV-2) Ag Rapid Test Kit was previously available as a home test in German and Austrian markets since May 20th, 2021. With the CE Mark, our test has received official approval following the traditional registration pathway and can now also be used in markets that have not established regulatory exemption pathways.

 

 

As the global economy starts to re-open, individuals or communities can follow the easy instruction of our test and detect whether they are infected with SARS-CoV-2 to avoid the further spread of the disease.

 

For further information, please send us an inquiry email: info@bioperfectus.com or  marketing_global@bioperfectus.com.

MOST READ

Bioperfectus Supports Cholera Elimination

SHANGHAI, CHINA, December 5, 2022—Jiangsu Bioperfectus Technologies Co., Ltd. (hereinafter referred to as “Bioperfectus”) is pleased to launch Vibrio Cholerae Real Time PCR Kits for human diagnosis and early warning surveillance.

2022-11-30

Client Story: A Race Against Time

Through a critical assessment of clinical evaluation and data validation, Bioperfetus successfully passed the Israeli ministry of health inspection. Bioperfetus was the only Chinese company on the procurement list and was asked to provide one million antigen rapid test kits for the Israeli ministry of health.

2022-11-15

Bioperfectus Granted MDA Approval in Malaysia for Nucleic Acid Extraction Systems

SHANGHAI, CHINA, November 14, 2022—Jiangsu Bioperfectus Technologies Co., Ltd. (hereinafter referred to as “Bioperfectus”), a leading global company in the molecular diagnostics market, today announced receipt of MDA (Medical Device Authority) approval in Malaysia for Nucleic Acid Extraction Systems, including Nucleic Acid SSNP-2000B, SSNP-3000A, SSNP-9600A, SMPE-960 and Extraction Rapid Kit (Magnetic Bead Method).

2022-11-14